首页> 美国卫生研究院文献>mAbs >Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules
【2h】

Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules

机译:Diabody-Ig:产生多价和多特异性抗体分子的新型平台

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of Db-Ig is composed of a diabody in the V -V orientation stabilized by fusion to antibody-derived homo- or heterodimerization domains, e.g., C 1/C or the heavy chain domain 2 of IgE (EHD2) or IgM (MHD2), further fused to an Fc region. In this study, we applied the Db-Ig format for the generation of tetravalent bispecific antibodies (2 + 2) directed against EGFR and HER3 and utilizing different dimerization domains. These Db-Ig antibodies retained the binding properties of the parental antibodies and demonstrated unhindered simultaneous binding of both antigens. The Db-Ig antibodies could be purified by a single affinity chromatography resulting in a homogenous preparation. Furthermore, the Db-Igs were highly stable in human plasma. Importantly, only one short peptide linker (5 aa) per chain is required to generate a Db-Ig molecule, reducing the potential risk of immunogenicity. The presence of a fully functional Fc resulted in IgG-like pharmacokinetic profiles of the Db-Ig molecules. Besides tetravalent bispecific molecules, this modular platform technology further allows for the generation of other multivalent molecules of varying specificity and valency, including mono-, bi-, tri- and tetra-specific molecules, and thus should be suitable for numerous applications.
机译:多价单或双特异性抗体对于治疗应用越来越感兴趣,例如有效的受体聚类和激活或双重靶向方法。在这里,我们提出了一个新的平台,用于生成类似Ig的分子,称为双抗体-Ig(Db-Ig)。 Db-Ig的抗原结合位点由V-V方向的双抗体组成,该双抗体通过与抗体衍生的同源或异源二聚结构域(例如C 1 / C或IgE的重链结构域2(EHD2))融合而稳定或IgM(MHD2),进一步融合至Fc区。在这项研究中,我们将Db-Ig格式应用于针对EGFR和HER3的四价双特异性抗体(2 + 2)的生成,并利用了不同的二聚化结构域。这些Db-Ig抗体保留了亲本抗体的结合特性,并证明了两种抗原的同时结合不受阻碍。 Db-Ig抗体可通过单亲和层析纯化,得到均一的制剂。此外,Db-Igs在人血浆中高度稳定。重要的是,每条链仅需要一个短肽接头(5个氨基酸)即可生成Db-Ig分子,从而降低了免疫原性的潜在风险。全功能Fc的存在导致Db-Ig分子的IgG样药代动力学特征。除了四价双特异性分子之外,这种模块化平台技术还允许生成具有不同特异性和价态的其他多价分子,包括单特异性,双特异性,三特异性和四特异性分子,因此应适合多种应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号